Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy

CONCLUSION: Given the limited real-world efficacy on EGFR-mutant NSCLC resistant to osimertinib and platinum-based chemotherapy, the development of more highly potent post-treatment therapies is warranted.PMID:37572265 | DOI:10.1007/s12325-023-02616-9

Source: Adv Data - August 12, 2023 Category: Epidemiology Authors: Hidetoshi Hayashi Makoto Nishio Michiko Takahashi Hiroaki Tsuchiya Mami Kasahara-Kiritani Source Type: research